Radiopharm Theranostics (ASX:RAD) Appoints Financial Industry Veteran to Board

Highlights

• Noel Donnelly has been appointed as a Non-Executive Director, effective 1 October 2024.
• Donnelly has over 25 years of leadership experience in operations, strategy, and finance within the biotechnology and biopharmaceutical sectors.
• RAD has been invited to present at the JonesResearch Virtual Radiopharma Day on 29 October 2024.

Radiopharm Theranostics Limited (ASX:RAD) has made a significant addition to its board with the appointment of Noel Donnelly as a Non-Executive Director, effective 1 October 2024. Donnelly brings over two decades of leadership experience in operations, strategy and finance within the biotechnology and biopharmaceutical sectors. He has an impressive track record of building cross-functional teams, enhancing corporate governance, and executing complex financial strategies that drive rapid company growth.

Donnelly’s rich experience  

Donnelly currently serves as the Chief Financial Officer at PepGen Inc, where he has overseen the financial strategy of the firm, including an initial public offering (IPO) in 2022 that raised US$120 million, followed by additional financing efforts that secured another US$90 million. Under his leadership, PepGen advanced two clinical assets into Phase 1 and Phase 2 trials.

Previously, Donnelly was CFO at EIP Pharma (now CervoMed), where he played a pivotal role in the company’s IPO planning phase. Over a 15-year tenure at Takeda/Shire PLC, he held multiple senior positions, including Vice President of R&D Business Operations. At Shire, Donnelly was instrumental in leading critical R&D integrations, managed over US$160 billion in integration planning and execution, and shaping the company’s portfolio management strategy to prioritise essential development assets.

Donnelly has significant experience in business partnering, valuation, investor relations, and decision support analysis, establishing himself as a trusted advisor to both executive leadership teams and boards of directors.

RAD to present at JonesResearch Radiopharma Day

The company has also announced that it has been invited to present at the JonesResearch Virtual Radiopharma Day, scheduled for Tuesday, 29 October 2024.

The event will feature panel discussions and fireside chats with both public and private companies in the radiopharmaceutical sector, along with opportunities for one-on-one meetings with investors.

The event is expected to attract institutional and professional investors from the US and other international markets. Topics in the panel discussion will include the potential benefits of novel targeting modalities, isotope supply and logistics, and new molecular targets.

RAD shares traded at AU$0.027 apiece at the time of writing on 2 October 2024, with a market cap of AU$60.84 million.